Ibio - Model RubrYc -Discovery Engine Platform Technology
Antibody discovery is challenging. Only 5 of every 5000 concepts make it into the clinic.1 Many antibody failures can be attributed to a lack of specificity for disease-causing cells versus healthy cells and a lack of efficacy – both potentially due to binding the wrong epitope.
Our patented RubrYc Discovery Engine2 aims to increase the likelihood of success. Using artificial intelligence (AI) to drive epitope-steered antibody discovery, the RubrYc Discovery Engine efficiently and consistently?delivers antibody candidates against difficult targets.
It does this by engineering mini-proteins embodying the structure of conformational epitopes, including subdominant epitopes, to discover traditionally challenging therapeutic antibodies. An epitope is the region of a target protein to which antibodies bind. The range of potential epitopes or binding sites on a target is enormous. But not all epitopes are created equally.
Traditional drug discovery has allowed the immune system to drive epitope selection and thus biasing antibody selection towards immunodominant epitopes. Often, the most efficacious epitope is not the immunodominant epitope and therefore the best therapeutic antibodies are missed without epitope steering.
The RubrYc Discovery Engine combines an Epitope Engineering Engine, an Antibody Library, and an Antibody Optimizer to increase the likelihood of success for antibody discovery against difficult targets.
Efficacy
Single-dose injection protects animals against challenge
DIVA
Absence of Ems response facilitates differentiation of infected from vaccinated animals
Flexibility
Potential for use in bait for feral hogs (natural virus reservoirs) without substantial purification, unlike live attenuated vaccines
Adaptability
Rapid initiation and scalability of manufacturing to support time-sensitive emergency response strategies
Reduced Time and Costs
Production with the FastPharming® System saves time and money
